Immunity to the G1 globular domain of the cartilage proteoglycan aggrecan can induce inflammatory erosive polyarthritis and spondylitis in BALB/c mice but immunity to G1 is inhibited by covalently bound keratan sulfate in vitro and in vivo
about
Commercial bovine proteoglycan is highly arthritogenic and can be used as an alternative antigen source for PGIA model.Treatment of spondyloarthropathies with antibodies against tumour necrosis factor alpha: first clinical and laboratory experiencesNovel approaches in the treatment of ankylosing spondylitis and other spondyloarthritides.Analysis of the CD8+ T cell response to the G1 domain of aggrecan in ankylosing spondylitis.Interactions of the innate and adaptive arms of the immune system in the pathogenesis of spondyloarthritisInduction of arthritis in BALB/c mice by cartilage link protein: involvement of distinct regions recognized by T and B lymphocytesArthritis induced by proteoglycan aggrecan G1 domain in BALB/c mice. Evidence for t cell involvement and the immunosuppressive influence of keratan sulfate on recognition of t and b cell epitopes.Antigen-specific B lymphocytes acquire proteoglycan aggrecan from cartilage extracellular matrix resulting in antigen presentation and CD4+ T-cell activation.Experimental immunity to the G1 domain of the proteoglycan versican induces spondylitis and sacroiliitis, of a kind seen in human spondylarthropathies.Presentation of the candidate rheumatoid arthritis autoantigen aggrecan by antigen-specific B cells induces enhanced CD4(+) T helper type 1 subset differentiation.Keratan Sulphate, a complex Glycosaminoglycan with Unique Functional Capability.Cellular immunity to the G1 domain of cartilage proteoglycan aggrecan is enhanced in patients with rheumatoid arthritis but only after removal of keratan sulfate.Progressive polyarthritis induced in BALB/c mice by aggrecan from normal and osteoarthritic human cartilage.T-cell responses to versican in ankylosing spondylitis
P2860
Q33757939-9862B293-803C-46A2-9B1F-41D140077A8CQ34071316-3D75D12F-0B1F-4834-A0F1-3B65C67F73CCQ35164736-02C10E50-A92D-4CA8-8AA6-C01EAE51D0D2Q35555515-F0AD7914-45E1-4652-804C-281C76F0F80FQ35694939-BC5D114A-63B1-4DA5-BAEE-CD9F959623ADQ35753511-DAB155BA-EAEC-46D3-B0B3-D70E98475289Q37380838-CF5745F3-BFA5-4C8C-878E-3D398CCB72E5Q39096503-366CBE60-3E70-4439-9D35-E13CF466CA3EQ44616895-972DA254-C9C9-4B06-A8F6-3900DB3A0DA0Q44761134-A6E78FE3-B754-4C55-9F3D-637685C972D1Q47860795-32A1E57B-DFB9-49F3-BB12-7401C0601B1FQ47973535-F8F25E50-38A1-4174-8886-5A43BE15F1F7Q47973548-7F95B5C9-2E51-406F-887A-7300B9D96B38Q57673802-036E84FC-EE26-4FE5-83F6-DB71F6DE2BE5
P2860
Immunity to the G1 globular domain of the cartilage proteoglycan aggrecan can induce inflammatory erosive polyarthritis and spondylitis in BALB/c mice but immunity to G1 is inhibited by covalently bound keratan sulfate in vitro and in vivo
description
article científic
@ca
article scientifique
@fr
articolo scientifico
@it
artigo científico
@pt
bilimsel makale
@tr
scientific article published on February 1996
@en
vedecký článok
@sk
vetenskaplig artikel
@sv
videnskabelig artikel
@da
vědecký článek
@cs
name
Immunity to the G1 globular do ...... n sulfate in vitro and in vivo
@en
Immunity to the G1 globular do ...... sulfate in vitro and in vivo.
@nl
type
label
Immunity to the G1 globular do ...... n sulfate in vitro and in vivo
@en
Immunity to the G1 globular do ...... sulfate in vitro and in vivo.
@nl
prefLabel
Immunity to the G1 globular do ...... n sulfate in vitro and in vivo
@en
Immunity to the G1 globular do ...... sulfate in vitro and in vivo.
@nl
P2093
P2860
P356
P1476
Immunity to the G1 globular do ...... n sulfate in vitro and in vivo
@en
P2093
A Guerassimov
J Y Leroux
L C Rosenberg
N Delaunay
S Banerjee
P2860
P304
P356
10.1172/JCI118458
P407
P577
1996-02-01T00:00:00Z